Currently, there are 98.63M common shares owned by the public and among those 97.96M shares have been available to trade.
The company’s stock has a 5-day price change of -11.33% and -38.15% over the past three months. FATE shares are trading -39.30% year to date (YTD), with the 12-month market performance down to -4.62% lower. It has a 12-month low price of $1.96 and touched a high of $8.83 over the same period. FATE has an average intraday trading volume of 1.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.40%, -26.53%, and -49.10% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Fate Therapeutics Inc (NASDAQ: FATE) shares accounts for 89.42% of the company’s 98.63M shares outstanding.
It has a market capitalization of $251.09M and a beta (3y monthly) value of 1.86. The earnings-per-share (ttm) stands at -$1.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.91% over the week and 11.75% over the month.
Analysts forecast that Fate Therapeutics Inc (FATE) will achieve an EPS of -0.43 for the current quarter, -0.46 for the next quarter and -1.63 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.49 while analysts give the company a high EPS estimate of -0.49. Comparatively, EPS for the current quarter was -0.45 a year ago. Earnings per share for the fiscal year are expected to increase by 0.50%, and -2.54% over the next financial year.
Piper Sandler coverage for the Fate Therapeutics Inc (FATE) stock in a research note released on June 17, 2024 offered a Overweight rating with a price target of $6. Wells Fargo was of a view on March 27, 2023 that the stock is Equal Weight, while H.C. Wainwright gave the stock Neutral rating on January 24, 2023, issuing a price target of $115- $7. Wedbush on their part issued Neutral rating on January 06, 2023.
